21 - 136 - TUBEROUS SCLEROSIS COMPLEX Flashcards

1
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Major features of TS, except

a. Hypomelanotic macules >3 atleast 5 cm in diameter
b. Shagreen patch
c. Ungual fibromas >2
d. Angiofibromas >3

A

a. Hypomelanotic macules >3 atleast 5 cm in diameter

27
Q

Minor features of TS, except

a. Confetti skin lesions
b. Dental enamel pits >2
c. Intraoral fibromas >2
d. Multiple renal cysts

A

b. Dental enamel pits >2

28
Q

Indications for use of mTOR inhibitors for TS, except

a. cardiac rhabdomyomas
b. LAM
c. Angiomyolipomas
d. Angiofibromas

A

d. Angiofibromas

29
Q

Skin manifestation that is associated with ipsilateral cerebral abnormalities and contralateral seizures

a. Shagreen patch
b. Fibrous plaque
c. Koenen tumor
d. Angiofibromas

A

b. Fibrous plaque

30
Q

Less common affected area by shagreen patch

a. Lower back - MC
b. Sacral region - MC
c. Upper Back
d. Forehead

A

c. Upper Back

31
Q

pattern of inheritance of TSC

32
Q

Tuberous sclerosis complex (TSC) is a genetic disease caused by mutations in what tumor-suppressor gene?

A

TSC1 or TSC2

33
Q

tuberous sclerosis complex affect what organs?

A

brain, heart, kidneys, lungs, and skin.

34
Q

common presentation of TSC during infancy

35
Q

skin findings of patients with TSC

A
  • hypomelanotic macules
  • facial angiofibromas
  • fibrous cephalic plaques
  • shagreen patches,
  • ungual fibromas
36
Q

what is the major criteria for hypomelanotic macules

A

Three or more hypopigmented macules measuring 5 mm or greater in longest dimension constitutes a major feature for the diagnosis of tuberous sclerosis

37
Q

AOP of ash-leaf spots

A

trunk and buttocks

38
Q

AOP of confetti skin lesions

A

legs below the knees or forearms

39
Q

AOP of facial angiofibromas

A

central face and are often concentrated in the alar grooves

extending symmetrically onto the cheeks and to the nose, nasal opening, and chin, with relative sparing of the upper lip and lateral face

40
Q

angiofibromas relatively spare what areas of the face?

A

upper lip and lateral face

41
Q

how many angiofibromas comprise a major feature?

42
Q

The development of multiple angiofibromas with onset later in adolescence or early adulthood is not specific for TSC and may, instead, indicate presence of what conditions?

A

multiple endocrine neoplasia Type 1 or Birt-Hogg-Dubé syndrome

43
Q

Most common location of shagreen patch

A

lower back to sacral region

44
Q

how many ungual fibromas should be present for it to be classified as a major feature for diagnosis of TSC?

45
Q

another name for multiple skin tags in tuberous sclerosis complex

A

Molluscum fibrosum pendulum

46
Q

intraoral fibromos are most common on what site?

47
Q

The first-line treatment of infantile spasms

A

vigabatrin

48
Q

This drug inhibits mTORC1 activity and treats TSC tumors

A

Sirolimus (rapamycin)

49
Q

Lesions characteristic of TSC

A
  • Juvenile-Onset Angiofibromas (≥3)
  • Hypomelanotic Macules (≥3)
  • Ungual Fibromas (≥2)
  • Fibrous Cephalic Plaque
  • Shagreen Patch
50
Q

clinical course and prognosis of TSC

A
  • They exhibit **decreased overall survival **compared with the general population.
  • The causes of premature death include** renal failure, intractable seizures, obstructive hydrocephalus, cardiac outflow obstruction, arrhythmia, respiratory failure, pneumothorax, and hemorrhage** from an aneurysm or a tumor, especially angiomyolipomas
  • Brain and heart tumors may cause death in infancy, whereas lung and kidney tumors are more likely to cause premature death in adulthood.
  • The prognosis for the individual patient depends on disease expressivity.
  • Some individuals have a normal life span with few medical complications.
51
Q

The management of TSC skin tumors has changed with the use of what drug classification?

A

mTOR inhibitors

Everolimus, Sirolimus